Serum ghrelin, but not obestatin, is a potential predictor of acute pancreatitis severity

Huilin Wang, PhD,a,b Mengbin Qin, PhDa, Zihai Liang, PhDa, Renjie Chang, PhDa, Hongzong Fu, MDa, Yule Wei, MDa, Guodu Tang, PhDa,∗

Abstract

The roles of ghrelin and obestatin in AP remain controversial. This study investigates the effects and the predictive value of serum ghrelin and obestatin levels in the early stage of AP.

A total of 193 consecutive patients with AP and 24 healthy controls were included. Patients were divided into mild acute pancreatitis (MAP), moderately severe acute pancreatitis (MSAP), and severe acute pancreatitis (SAP) groups. Serum levels of ghrelin and obestatin were measured on the first, third, and fifth days of hospitalization. The predictive value of serum ghrelin and obestatin levels on the first day in AP was examined using receiver-operating characteristic (ROC) curves.

On the first day of hospitalization, the mean serum ghrelin level was significantly lower in patients with AP than in controls (P < .01). The serum ghrelin concentration decreased with increasing AP severity and was lower in patients with SAP than in those with MAP and MSAP (P < .05). It increased gradually from the first to the fifth day after treatment. ROC curves demonstrated that the serum ghrelin level on the first day had some predictive value for AP severity (area under the ROC curve = 0.646), with an optimal cut-off value of 87.83 pg/mL. Logistic regression showed that the serum ghrelin level had independent predictive value for non-MAP (odds ratio = 10.94; 95% confidence interval, 5.08–23.55; P < .01). The serum obestatin level did not differ significantly between patients with AP and controls and had the limited predictive value for non-MAP (area under the ROC curve = 0.564). However, the serum obestatin concentration showed a “warning” effect regarding AP etiology; on the first day of treatment, it was significantly lower in patients with AP of hypertriglyceridemic etiology than in those with AP of biliary, alcohol-related, and other etiologies (P = .05, P = .031, and P = .029, respectively).

Serum ghrelin and obestatin levels may be related to the progression of AP in the early stage. Only the serum ghrelin level is a potential predictor of AP severity in the early stage. Obestatin may be involved in the pathogenesis of AP caused by hypertriglyceridemia.

Abbreviations: AP = acute pancreatitis, AUC = area under the receiver-operating characteristic curve, BISAP = Bedside Index for Severity in Acute Pancreatitis, BMI = body mass index, CT = computerized tomography, MAP = mild acute pancreatitis, MCTSI = Modified Computed Tomography Severity Index, MSAP = moderately severe acute pancreatitis, ROC = receiver-operating characteristic, SAP = severe acute pancreatitis, WBC = white blood cell.

Keywords: acute pancreatitis, ghrelin, obestatin, predictive value, severity

1. Introduction

Acute pancreatitis (AP) is one of the most common diseases of the digestive system, and its incidence is increasing.1 The majority of patients with mild acute pancreatitis (MAP) recover within 5 to 7 days with aggressive intravenous hydration and fasting. In about 20% of patients, however, the disease progresses to severe acute pancreatitis (SAP), with up to 10% to 30% mortality.2 Because of the complex and variable clinical course of the disease, doctors have difficulty with accurate determination of the prognosis of SAP in the early stage, even with the use of advanced scoring systems.1,3 Early detection of potential SAP is crucial for adequate treatment and the reduction of mortality. For this reason, the prognostic roles of several cytokines and serum biomarkers in AP have been investigated, but the results have been unsatisfactory.6

Ghrelin was first discovered and isolated from rat stomach X/A-like cells.7 It can stimulate growth hormone secretion by binding to the growth hormone receptor. Initial studies focused on its roles in endocrine, energy balance, appetite, and gastrointestinal regulation.8,9 Recently, the anti-inflammatory and immunomodulatory activities of ghrelin, including in AP, have been examined.10,11 Some studies have shown that ghrelin levels are related to the progression of AP, but cut-off values for the effective concentration have been inconsistent.12,13 Thus, more studies of the effects of serum ghrelin level on AP are needed.

Obestatin, derived from the same prohormone as ghrelin, contributes to the reduction of gastrointestinal motility, appetite suppression, weight loss, and increased memory function in
mammals; these roles contrast with the functions of ghrelin.\textsuperscript{[14,15]} The administration of obestatin inhibited the development of AP in a rat model,\textsuperscript{[16,17]} but few studies have investigated the role of endogenous obestatin in human patients with AP.\textsuperscript{[18]} Thus, this study was designed to assess serum ghrelin and obestatin levels in patients with AP, and to determine whether these 2 indexes have predictive value as biomarkers in AP.

2. Materials and methods

2.1. Participants and baseline data collection

The Ethics Committee of the First Affiliated Hospital of Guangxi Medical University approved this study, and all subjects provided written informed consent. Patients with AP who were admitted to our Department of Gastroenterology between November 2012 and February 2016 were recruited consecutively. AP diagnoses were based on the revised Atlanta classification.\textsuperscript{[19]} AP was defined as the presence of local and/or systemic complications lasting 48 hours or more, and/or exacerbation of comorbidity. MAP was defined as persistent organ failure lasting 48 hours, and/or multiple local complications, according to the Atlanta classification.\textsuperscript{[20]} BMI was calculated as weight (in kilograms) divided by height (in meters) squared. Non-MAP was defined as the absence of organ failure and/or systemic complications lasting <48 hours, and/or exacerbation of comorbidity. MAP was defined as persistent organ failure lasting >48 hours, and/or multiple local complications, according to the Atlanta classification.\textsuperscript{[21]} BMI was calculated as weight (in kilograms) divided by height (in meters) squared. Non-MAP was defined as the absence of organ failure and/or systemic complications lasting <48 hours, and/or exacerbation of comorbidity.

AP diagnoses were based on the revised Atlanta classification.\textsuperscript{[13,22]} MAP was defined as the absence of organ failure and local or systemic complications. Moderately severe acute pancreatitis (MSAP) was defined as the presence of local and/or systemic complications lasting <48 hours, and/or exacerbation of comorbidity. SAP was defined as persistent organ failure lasting >48 hours, and/or multiple local complications, according to the Atlanta classification.\textsuperscript{[21]} BMI was calculated as weight (in kilograms) divided by height (in meters) squared. Non-MAP was defined as the absence of organ failure and/or systemic complications lasting <48 hours, and/or exacerbation of comorbidity.

2.2. Definitions

AP diagnoses were based on the revised Atlanta classification.\textsuperscript{[13,22]} MAP was defined as the absence of organ failure and local or systemic complications. Moderately severe acute pancreatitis (MSAP) was defined as the presence of local and/or systemic complications lasting <48 hours, and/or exacerbation of comorbidity. SAP was defined as persistent organ failure lasting >48 hours, and/or multiple local complications, according to the Atlanta classification.\textsuperscript{[21]} BMI was calculated as weight (in kilograms) divided by height (in meters) squared. Non-MAP was defined as the absence of organ failure and/or systemic complications lasting <48 hours, and/or exacerbation of comorbidity.

The Bedside Index for Severity in Acute Pancreatitis (BISAP) was completed within 24 hours of each patient’s admission, and the Ranson criteria were applied within 48 hours of admission.\textsuperscript{[19,20]} All patients underwent contrast-enhanced CT within 48 hours of admission. Modified Computed Tomography Severity Index (MCTSI) scores were calculated within 48 hours after CT examination. Each clinical score was calculated based on the most extreme laboratory data obtained within 48 hours of admission.

2.3. Measurement

Venous blood samples were collected from subjects after overnight fasting. Blood samples were collected from patients on the first, third, and fifth days of hospitalization. The samples were centrifuged immediately, and the serum was stored at -80°C until analysis. The serum levels of neutrophils, albumin, calcium, and triglycerides, and the white blood cell (WBC) count, were measured in samples collected on the first day of hospitalization. The serum levels of obestatin and ghrelin were determined using RayBio’s Human Enzyme Immunoassay kit (RayBiotech, Norcross).

2.4. Statistical analysis

Statistical analysis was performed using SPSS 16.0 software (SPSS Inc., Chicago, IL). Continuous variables are presented as means and standard deviations. Data from patients and controls were compared using Student’s t test. Differences in ghrelin and obestatin levels among groups were examined using analysis of variance. The sensitivity and specificity of each index were evaluated. A receiver-operating characteristic (ROC) curve was used to describe the performance of continuous variables. The predictive accuracy of ghrelin and obestatin levels in patients with AP was examined using the area under the receiver-operating characteristic curve (AUC). Optimal cut-off values were determined from ROC curve analyses by calculating the minimum distances from graph coordinates with maximum sensitivity and specificity. The AUC results were examined using multivariate logistic regression analyses with forced inclusion of explanatory variables. Multiple comparisons of variance were adjusted for age; WBC count; neutrophil, albumin, calcium, and triglyceride levels; and Ranson, BISAP, and MCTSI scores according to the etiology and severity of AP. To further test the predictive value of non-MAP, we used serum ghrelin and obestatin data from the first day. The significance level was set to $P < .05$.

3. Results

3.1. Baseline characteristics of subjects

Table 1 shows the baseline characteristics of subjects included in the study. A total of 193 patients (121 males, 72 females; mean age, 49.8 ± 14.7 years) with AP (MAP, n = 94; MSAP, n = 70; SAP, n = 29) were recruited. The time from the first symptom onset to hospital admission ranged from 6 to 48 hours. Twenty-four healthy controls (15 males, 9 females; mean age, 51.8 ± 14.2 years) were included in the study (Table 1).

3.2. Serum ghrelin and obestatin levels according to AP severity

Serum ghrelin levels were much higher in healthy controls than in patients with MAP, MSAP, and SAP (all $P < .001$). They decreased with increasing AP severity and were significantly higher in patients with MAP than in those with MSAP and SAP ($P < .05$ and $P < .01$, respectively, Fig. 1A, Table 2). No significant difference in the serum ghrelin level was found between patients with MSAP and those with SAP (Fig. 1A, Table 2). After treatment, this concentration increased gradually from the first day to the fifth day. Serum ghrelin levels on the third day were lower in patients with SAP than in those with MAP ($P < .01$); no difference was observed between patients with MSAP and those with SAP. On the fifth day after treatment, the serum ghrelin concentration was lower in patients with SAP than in those with MSAP and SAP ($P < .05$ and $P < .01$, respectively; Table 2). The serum ghrelin concentration thus varied with AP severity.

In contrast to ghrelin, obestatin levels tended to be higher in patients with AP than in controls, but the difference was not significant. Serum obestatin levels did not differ among patients with MAP, MSAP, and SAP (Fig. 1B, Table 3). The obestatin concentration decreased from the first day to the fifth day after treatment, and levels on the third and fifth days did not differ according to AP severity (Table 3). Thus, the serum obestatin level was not correlated with AP severity.
Laboratory values,
Ghrelin, pg/mL
Hormone level First day Third day Fifth day Changes in ghrelin levels of hospitalization.
AP etiology, n, %

**Table 1**
Baseline characteristics of patients according to AP severity.

| Characteristic | All (n = 193) | MAP (n = 94) | MSAP (n = 70) | SAP (n = 29) | MAP vs MSAP | MSAP vs SAP | SAP vs MAP |
|----------------|--------------|--------------|---------------|--------------|-------------|-------------|------------|
| Age, y         | 49.84 ± 14.70 | 49.65 ± 14.10 | 49.85 ± 14.73 | 52.52 ± 13.46 | .776        | .948        | .453       |
| Sex, male/female | 12/72       | 59/35        | 43/27         | 19/10        | .861        | .702        | .788       |
| BMI, kg/m²     | 22.8 ± 4.3   | 23.1 ± 4.5   | 22.9 ± 4.1    | 21.8 ± 3.8   | .718        | .268        | .156       |
| AP etiology, n, % |            |              |               |              |             |             |            |
| Biliary, B     | 67           | 40 (50.6)    | 18 (26.9)     | 9 (13.4)     | –           | –           | –          |
| Alcohol-related, A | 61        | 28 (45.9)    | 21 (34.4)     | 12 (19.7)    | –           | –           | –          |
| Hypertglyceridemia, H | 25     | 5 (20)       | 15 (60)       | 5 (20)       | –           | –           | –          |
| Other, O       | 40           | 21 (52.9)    | 16 (40)       | 3 (7.9)      | –           | –           | –          |
| B/A/H/O        |              | 40/28/5/21   | 18/21/15/16   | 9/12/5/3     | .60         | .414        | .048       |
| Laboratory values, first day of hospitalization |              |              |               |              |             |             |            |
| WBC, 10⁹/L     | 12.75 ± 5.55 | 13.22 ± 5.81 | 12.15 ± 5.13  | 12.64 ± 5.70 | .223        | .279        | .622       |
| Neutrophils, %  | 77.39 ± 14.01| 78.16 ± 14.30| 76.43 ± 14.11 | 77.18 ± 13.09| .438        | .810        | .744       |
| Albumin, g/L    | 35.72 ± 5.72 | 36.26 ± 5.74 | 35.43 ± 5.59  | 34.62 ± 5.93 | .359        | .521        | .178       |
| Calcium, mmol/L | 2.04 ± 0.25  | 2.07 ± 0.25  | 2.01 ± 0.25   | 2.03 ± 0.22  | .091        | .754        | .350       |
| Triglycerides, mmol/L | 3.25 ± 3.93 | 2.86 ± 3.53  | 3.10 ± 3.71   | 4.87 ± 5.6   | .694        | .041        | .016       |
| Clinical scores |              |              |               |              |             |             |            |
| Ranson          | 1.67 ± 1.54  | 1.42 ± 1.36  | 1.67 ± 1.38   | 2.52 ± 2.10  | .279        | .011        | .001       |
| BISAP           | 1.05 ± 1.01  | 0.83 ± 0.98  | 1.13 ± 0.87   | 1.55 ± 1.21  | .117        | .256        | .017       |
| MCTSI           | 4.01 ± 3.28  | 2.77 ± 2.53  | 4.89 ± 3.52   | 5.93 ± 3.32  | .000        | .417        | .000       |

*Values are expressed as mean ± standard deviation, n, or n (%).
A = alcohol-related, B = biliary, AP = acute pancreatitis, BMI = body mass index, BISAP = Bedside Index for Severity in Acute Pancreatitis, H = hypertrglyceridemia, MAP = mild acute pancreatitis, MSAP = moderately severe acute pancreatitis, O = other, SAP = severe acute pancreatitis, WBC = white blood cells.

---

**Table 2**
Changes in ghrelin levels of hospitalization.

| Hormone level | First day | Third day | Fifth day |
|---------------|-----------|-----------|-----------|
| Ghrelin, pg/mL |           |           |           |
| MAP           | 112.10 ± 109.52 | 121.67 ± 99.28 | 127.87 ± 103.32 |
| MSAP          | 70.58 ± 86.67   | 87.82 ± 93.63   | 109.02 ± 117.16 |
| SAP           | 49.96 ± 69.43    | 68.04 ± 69.10    | 63.33 ± 38.07   |
| Total         | 101.34 ± 103.72  | 101.33 ± 105.17  | 111.33 ± 103.92  |
| Control       | 211.04 ± 69.91   | –         | –         |

*P-values, statistically significant in bold

| Control vs MAP | .000 | – | – |
| Control vs MSAP | .000 | – | – |
| Control vs SAP | .000 | – | – |
| MAP vs MSAP | .044 | 0.79 | 6.54 |
| MAP vs SAP | .003 | 0.05 | .000 |
| MSAP vs SAP | .763 | 54.2 | .013 |

*Values are expressed as mean ± standard deviation.
MAP = mild acute pancreatitis, MSAP = moderately severe acute pancreatitis, SAP = severe acute pancreatitis.

---

**Figure 1.** Serum levels of ghrelin (A) and obestatin (B) on the first day of hospitalization in patients with AP. Values are expressed as means ± standard deviations. The significance between the AP group and the control group, *P < .05, **P < .01, ***P < .001; the significance between AP groups, +P < .05, ++P < .01, +++P < .001; AP = acute pancreatitis, MAP = mild acute pancreatitis, MSAP = moderately severe acute pancreatitis, O = other, SAP = severe acute pancreatitis, WBC = white blood cells.

---

**Table 3**
Changes in obestatin levels of hospitalization.

| Hormone level | First day | Third day | Fifth day |
|---------------|-----------|-----------|-----------|
| Obestatin, pg/mL |        |           |           |
| MAP           | 39.33 ± 58.54 | 32.71 ± 36.82 | 31.71 ± 33.65 |
| MSAP          | 45.81 ± 60.48   | 34.43 ± 45.71   | 34.10 ± 34.27   |
| SAP           | 48.47 ± 61.09    | 40.06 ± 66.54    | 37.93 ± 55.33    |
| Total         | 42.79 ± 56.82    | 36.21 ± 58.13    | 35.13 ± 42.06    |
| Control       | 34.20 ± 22.64    | –         | –         |

*P-values, statistically significant in bold

| Control vs MAP | .375 | – | – |
| Control vs MSAP | .704 | – | – |
| Control vs SAP | .366 | – | – |
| MAP vs MSAP | .473 | 54.2 | .566 |
| MAP vs SAP | .826 | 800.0 | .790 |
| MSAP vs SAP | .469 | 570.0 | .506 |

*MAP = mild acute pancreatitis, MSAP = moderately severe acute pancreatitis, SAP = severe acute pancreatitis.

---


mL was an independent risk factor for non-MAP (odds ratio = 3.5. Risk factors for non-MAP

In logistic regression models, the serum ghrelin level was a potentially predictor for the diagnosis and treatment of AP.

No difference among etiology groups was found in the serum ghrelin levels differed according to AP etiology. Using ROC analysis, we determined that a cut-off value of 87.83 pg/mL for the serum ghrelin level had some predictive value for non-MAP. Logistic regression further verified the predictive value of ghrelin for non-MAP, suggesting that ghrelin is a potentially valuable target for the diagnosis and treatment of AP.

3.4. Predictive value of ghrelin and obestatin levels for AP severity

Only the ghrelin level showed good predictive value for AP severity (AUC = 0.646); the optimal cut-off value was 87.83 pg/mL, with sensitivity and specificity values of 0.489 and 0.869, respectively (P < .01). The ghrelin level had little predictive value (AUC = 0.646; the optimal cut-off value was 87.83 pg/mL, with sensitivity and specificity values of 0.489 and 0.869, respectively (P < .01)). The results further confirmed that ghrelin was a potentially predictor for the diagnosis and treatment of AP.

3.5. Risk factors for non-MAP

In logistic regression models, the serum ghrelin level < 87.83 pg/mL was an independent risk factor for non-MAP (odds ratio = 10.94; 95% confidence interval, 5.08–23.55; P < .01) (Table 5). The serum obestatin level was not an independent risk factor for non-MAP.

4. Discussion

In the present study, we measured serum ghrelin and obestatin levels in patients with early-stage AP and explored their predictive value for AP severity. Serum ghrelin levels were lower and serum obestatin levels were higher in patients with AP than in healthy controls, suggesting that both hormones are involved in the development of AP. In addition, serum ghrelin and obestatin levels differed according to AP etiology. Using ROC analysis, we determined that a cut-off value of 87.83 pg/mL for the serum ghrelin level had some predictive value for non-MAP. Logistic regression further verified the predictive value of ghrelin for non-MAP, suggesting that ghrelin is a potentially valuable target for the diagnosis and treatment of SAP.

Table 4

| Variable          | Biliary (B) | Alcohol-related (A) | Hypertriglyceridemia (H) | Other (O) | H vs B | H vs A | H vs O |
|-------------------|-------------|---------------------|--------------------------|-----------|--------|--------|--------|
| Ghrelin, pg/mL    | 81.80±97.21 | 73.72±79.28         | 105.18±126.00            | 107.55±110.73 | .345   | .211   | .928   |
| Obestatin, pg/mL  | 52.68±75.51 | 43.84±51.74         | 11.35±12.99              | 45.76±51.17 | .005   | .031   | .229   |
| Age, y            | 51.75±14.80 | 48.13±14.20         | 46.81±15.18              | 50.66±15.01 | .180   | .723   | .325   |
| Laboratory values |             |                     |                          |           |        |        |        |
| WBC, 10^9/L       | 12.05±5.65  | 13.01±5.02          | 14.22±5.41               | 12.77±6.13 | .119   | .389   | .326   |
| Neutrophils, %    | 77.83±13.24 | 78.20±17.63         | 80.64±9.38               | 76.77±11.32 | .425   | .215   | .300   |
| Albumin, g/L      | 36.02±5.9   | 35.11±5.38          | 36.08±6.09               | 35.91±5.83 | .967   | .507   | .910   |
| Calcium, mmol/L   | 2.06±0.22   | 2.06±0.26           | 2.01±0.19                | 2.02±0.28  | .457   | .464   | .852   |
| Triglycerides, mmol/L | 2.58±3.66 | 2.39±2.63           | 10.42±3.82               | 2.01±1.86  | <.001  | <.001  | <.001  |
| Clinical scores   |             |                     |                          |           |        |        |        |
| Ranson            | 1.75±1.70   | 1.72±1.60           | 1.81±1.40                | 1.43±1.23  | .877   | .812   | .357   |
| BISAP             | 1.13±1.06   | 1.03±1.06           | 1.38±0.87                | 0.77±0.86  | .320   | .171   | .023   |
| MCTSI             | 4.35±3.53   | 3.8±3.35            | 5.43±3.41                | 3.09±2.78  | .745   | .329   | .067   |

Values are expressed as mean ± standard deviation.

A = alcohol-related, AP = acute pancreatitis, B = biliary, BISAP = Bedside Index for Severity in Acute Pancreatitis, H = hypertriglyceridemia, MAP = mild acute pancreatitis, MCTSI = Modified Computed Tomography Severity Index, MSAP = moderately severe acute pancreatitis, O = other, SAP = severe acute pancreatitis, WBC = white blood cells.
Ghrelin has been reported to regulate central and peripheral lipid metabolism.\(^\text{23}\) It was recently shown to play an anti-inflammatory role in some critical illnesses, including AP.\(^\text{24}\) Administration of ghrelin had a protective effect on AP of diverse causes, accompanied by decreased serum levels of pro-inflammatory factors, improvement in pancreatic blood flow, and increased DNA synthesis.\(^\text{17,23}\) However, reports on serum ghrelin levels in patients with AP have been inconsistent. In our study, serum ghrelin levels at admission were significantly lower in patients with AP than in healthy controls. This result is in agreement with the findings of Panek et al.,\(^\text{26}\) but contrasts with the results of Daniel et al.,\(^\text{13}\) who found higher serum ghrelin levels in patients with AP than in controls. This discrepancy may be due to differences in the timing of blood sample collection and AP etiology.

Obestatin is receiving increasing attention because it plays a crucial role in tissue and circulating lipid metabolism. Several studies have shown that acute obestatin treatment and chronic treatment with native or modified obestatin can alter triglyceride levels,\(^\text{14,27}\) suggesting that obestatin is involved in the lipid metabolism. In this study, serum obestatin levels in patients with AP were elevated at admission, but were not correlated with AP severity; these findings are consistent with those of Kanat et al.\(^\text{18}\) Unlike serum ghrelin levels, serum obestatin levels differed significantly between patients with AP caused by hypertriglyceridemia and those with AP of other etiologies. In addition, these patients had higher BISAP, Ranson, and MCTSI scores than did patients with AP of other etiologies, and the hypertriglyceridemia etiology group included significantly fewer patients with MAP than did the other 3 etiology groups. These findings indicate that patients with AP caused by hypertriglyceridemia tend to develop severe disease.

Several limitations of this study should be noted. First, we did not measure serum ghrelin and obestatin levels at the time of discharge; thus, we do not know whether these levels had returned to normal, which would have provided useful information about patients’ recovery. Second, this study included a large proportion of patients with non-MAP because our hospital is the largest in the region, which could lead to selection bias. Third, although we examined a larger group of patients than included in other published studies, the samples of patients with AP of different etiologies were small, which limited subgroup analyses. Fourth, although we failed to show that the serum obestatin level has predictive value for non-MAP, the inclusion of more patients with AP caused by hypertriglyceridemia might improve the predictive performance of this variable. Thus, our results should be interpreted with caution, and the predictive value of serum ghrelin and obestatin levels in AP should be examined further.

### 5. Conclusions

In summary, this study investigated the role of serum ghrelin and obestatin in early-stage AP. It demonstrated that serum ghrelin and obestatin may be involved in the development of AP. The serum ghrelin level on the first day of hospitalization was related to AP degree and is thus a potential predictor of AP severity. In contrast, the results of the present study do not support the value of obestatin as an indicator of AP severity. However, obestatin levels differed significantly between patients with AP caused by hypertriglyceridemia and those with AP of other etiologies, which suggests that this marker may have a “warning” effect with regard to AP development. The roles of ghrelin and obestatin in AP need to be confirmed with multicenter studies including more patients with AP.

### References

1. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013;144:1252–61.
2. Hamada S, Masamune A, Shimosegawa T. Management of acute pancreatitis in Japan: analysis of nationwide epidemiological survey. World J Gastroenterol 2016;22:6335–44.
3. Zhu HH, Jiang LL. Serum inter-cellular adhesion molecule 1 is an early marker of diagnosis and prediction of severe acute pancreatitis. World J Gastroenterol 2012;18:2554–60.
4. Agnew A, Calderwood D, Chevallier OP, et al. Chronic treatment with a stable obestatin analog significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in rats. Peptides 2011;32:735–62.
5. Steenby H, Hartman H, Johansen D, et al. Predictive capacity of biomarkers for severe acute pancreatitis. Eur Surg Res 2016;56:153–63.
6. Turkoglu A, Boyuk A, Tantriverdi MH, et al. The potential role of BMI, plasma leptin, resistin, ghrelin and IL-18 in alcoholic acute pancreatitis. World J Gastroenterol 2014;20:6393–8.
7. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000;141:4255–61.
8. Muccioli G, Baragi E, Granata R, et al. Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology 2007;86:147–64.
9. Broglio F, Prodam F, Me E, et al. Ghrelin: endocrine, metabolic and cardiovascular actions. J Endocrinol Invest 2003;26(5 suppl):23–5.
10. Mao Y, Tokudome T, Kishimoto I, et al. Endogenous ghrelin attenuates pressure overload-induced cardiac hypertrophy via a cholinergic anti-inflammatory pathway. Hypertension 2015;65:1238–44.
11. Sun GX, Ying R, Li M, et al. Ghrelin attenuates renal fibrosis and inflammation of obstructive nephropathy. J Urol 2015;193:2107–15.
12. Jaworek J, Knurr M, Klingenberg P, et al. Obestatin prevents plasma triglyceride levels in rats during refeeding. Horm Res Paediatr 2015;83:341–50.
13. Daniel P, Lesniowska A, Jasinska A, et al. Usefulness of assessing circulating levels of resistin, ghrelin, and IL-18 in alcoholic acute pancreatitis. Dig Dis Sci 2010;55:2982–7.
14. Nagaraj S, Peddiya SS, Manjappara UV. Fragment analogs as better mimics of obestatin. Regul Pept 2009;158:145–8.
15. Brumetti I, Di Nisio C, Recinella E, et al. Obestatin inhibits dopamine release in rat hypothalamus. Eur J Pharmacol 2010;641:142–7.
16. Bukowczan J, Gieszkowski J, Warzecha Z, et al. Therapeutic effect of obestatin in the course of cerulein-induced acute pancreatitis. Pancreas 2016;45:700–6.
17. Bukowczan J, Warzecha Z, Czeranowicz P, et al. Therapeutic effect of ghrelin in the course of ischemia/reperfusion-induced acute pancreatitis. Curr Pharm Des 2015;21:2284–90.

### Table 5

| Risk factors for non-MAP. | B       | S.E    | Wals    | df | Sig.  | Exp (B) | EXP (B)95%CI |
|---------------------------|---------|--------|---------|----|-------|---------|--------------|
| **Ghrelin**               | 2.392   | 0.301  | 37.404  | 1  | 0.000  | 10.940   | 5.082        |
| **Constants**             | -1.723  | 0.343  | 25.182  | 1  | 0.000  | 1.723    | 0.343        |

\(B = \text{beta} \quad \text{S.E.} = \text{standard error} \quad \text{MAP} = \text{modified acute pancreatitis} \quad \text{S.E.} = \text{standard error} \quad \text{CI} = \text{confidence interval} \quad \text{df} = \text{degrees of freedom} \quad \text{Exp} = \text{exponential} \quad \text{Sig} = \text{significance} \quad \text{95%CI} = \text{95% confidence interval} \quad MAP = \text{modified acute pancreatitis}
[18] Kanat BH, Ayten R, Aydin S, et al. Significance of appetite hormone ghrelin and obestatin levels in the assessment of the severity of acute pancreatitis. Turk J Gastroenterol 2014;25:309–13.

[19] Ranson JH, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet 1974;139:69–81.

[20] Wu BU, Johannes RS, Sun X, et al. The early prediction of mortality in acute pancreatitis: a large population-based study. Gut 2008;57:1698–703.

[21] Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013;62:102–11.

[22] Dellinger EP, Forsmark CE, Layer P, et al. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. Ann Surg 2012;256:875–80.

[23] Lim CT, Kola B, Korbonits M. The ghrelin/GOAT/GHS-R system and growth hormone/GH/IGF-1 in the therapeutic effect of ghrelin in the course of cerulein-induced acute pancreatitis. J Physiol Pharmacol 2010;61:599–606.

[24] Panek J, Bonior J, Pieton J, et al. Serum leptin and ghrelin levels in patients in the early stages of acute biliary pancreatitis and different degrees of severity. Pol Przegl Chir 2014;86:211–7.

[25] Miegueu P, St Pierre D, Broglie F, et al. Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes. J Cell Biochem 2011;112:704–14.